Curriculum Vita MARK A. GREEN - Purdue College of Pharmacy ...

Curriculum Vita
MARK A. GREEN
Division of Nuclear Pharmacy
Department of Industrial and Physical Pharmacy
School of Pharmacy and Pharmacal Sciences
Purdue University
West Lafayette, Indiana 47907-2091
EDUCATION
Ph.D. Indiana University, Bloomington, Indiana, 1982
Major: Inorganic Chemistry Minor: Organic Chemistry
B.S. Rose-Hulman Institute of Technology, Terre Haute, Indiana, 1978
Magna Cum Laude; Major: Chemistry
PROFESSIONAL EXPERIENCE
8/01-present
Professor, Division of Nuclear Pharmacy, Department of Industrial and Physical Pharmacy,
School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana.
Conducting research relating to the design and development of new radiopharmaceuticals
labeled with metal radionuclides. Research emphasizes tracers for non-invasive evaluation of
regional perfusion with positron emission tomography, and strategies for tumor-selective
targeting of radiopharmaceuticals. Teaching duties include nuclear pharmacy instruction for
undergraduate pharmacy students, post-graduate instruction in the Purdue University Nuclear
Pharmacy Certificate Program, and graduate training in nuclear pharmacy and
radiopharmaceutical sciences.
7/94-7/01 Professor of Medicinal Chemistry, Division of Nuclear Pharmacy, Department of Medicinal
Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue
University, West Lafayette, Indiana.
3/90-present
Adjunct Assistant Professor of Radiology, Division of Nuclear Medicine, Department of
Radiology, Indiana University School of Medicine, Indianapolis, Indiana.
7/90-6/94 Associate Professor of Medicinal Chemistry, Division of Nuclear Pharmacy, Department of
Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue
University, West Lafayette, Indiana.
7/87-6/90 Assistant Professor of Nuclear Pharmacy, Department of Medicinal Chemistry and
Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue University, West
Lafayette, Indiana.
7/85-7/87 Assistant Professor, Department of Radiology, University of Minnesota Medical School,
Minneapolis, Minnesota. Joint appointment, College of Pharmacy, Department of Medicinal
Chemistry. Conducted chemical research relating to the development of new
radiopharmaceuticals labeled with metal radioisotopes. Teaching duties included undergraduate
instruction in nuclear pharmacy, along with radiology resident instruction in
radiopharmaceutical chemistry.
1

PROFESSIONAL EXPERIENCE (continued from page 1)
8/82-6/85 Postdoctoral Research Associate with Professor Michael J. Welch, Washington University
School of Medicine, St. Louis, Missouri. Involved in the synthesis of radiopharmaceuticals
labeled with short half-lived radionuclides (Tc-99m, Ga-68, In-111). Developed a gallium-68
radiopharmaceutical suitable for assessment of regional myocardial blood flow by positron
emission tomography (PET).
1/84-5/84 Taught senior level inorganic chemistry course for the University College Division of
Washington University.
9/78-8/82 Conducted research with Professor Kenneth G. Caulton on the structure and reactivity of
transition metal polyhydride complexes and their use in homogenous catalysis. This work
involved the synthesis of air-sensitive compounds and the examination of their thermal and
photochemical reactivity utilizing techniques such as: gas and column chromatography,
multinuclear NMR, IR, UV/VIS, and mass spectrometry. Title of Ph.D. thesis – "Photochemical
Activation of Rhenium and Osmium Polyhydride Complexes for Synthesis and Catalysis."
9/78-5/79 Associate Instructor, Indiana University. Supervised an undergraduate organic chemistry
laboratory.
PERSONAL
Date of Birth: September 10, 1956
Place of Birth: Sidney, Ohio
HONORS AND AWARDS
Gold Medal Scientific Exhibit, Society of Nuclear Medicine, 43rd Annual Meeting, Denver, 1996
Twelfth Tetalman Memorial Award (In Recognition of Outstanding Acheivement as a Young Investigator),
The Society of Nuclear Medicine, June, 1992
NIH Research Career Development Award, from the National Heart, Lung, and Blood Institute, 8/86-7/91
Bronze Medal Scientific Exhibit, Society of Nuclear Medicine, 34th Annual Meeting, Toronto, 1987
Chairman/Chairman-elect, Southern Indiana Section-ACS, 1980-81
Indiana University Graduate Student Fellowship, 1978
W.A. Noyes Chemistry Award, 1978
Tau Beta Pi, 1977
Omega Chi Episilon, 1977
Indiana Society of Professional Engineers Auxiliary Scholarship, 1977-78
Indiana State Scholarship, 1974-78
PROFESSIONAL ORGANIZATIONS
American Chemical Society, 1977-present
Society of Nuclear Medicine, 1983-present
Sigma Xi (Scientific Research Society), 1988-present
International Society of Cerebral Blood Flow and Metabolism, 1991-present
Institute for Clinical PET, 1991-present;
Society of Nuclear Imaging in Drug Development, 2000-present
American Association for Cancer Research, 1997-present
2

PUBLICATIONS
1. "Photochemistry of Transition Metal Hydrides: Dimerization of ReH 5 (PMe 2 Ph) 3 Following Photodissociation
of Phosphine," J. Am. Chem. Soc., 103, 695-696 (1981). M.A. Green, J.C. Huffman, and K.G. Caulton.
2. "Ligand Scavenging and Catalytic Utilization of the Phototransient ReH 5 (PMe 2 Ph) 2 ," J. Organomet. Chem.,
218, C39-43 (1981). M.A. Green, W.K. Rybak, J.C. Huffman, J.J. Ziolkowski, and K.G. Caulton.
3. "Could One Have Five? The Synthesis and Structure of Re 2 H 4 (PMe 2 Ph) 4 [P(OCH 2 ) 3 CEt] 2 and Its Conjugate
Acid," J. Am. Chem. Soc., 104, 2319-2320 (1982). M.A. Green, J.C. Huffman, and K.G. Caulton.
4. "Electrophilic Attack as a Route to Coordinative Unsaturation," Proceedings of the Climax Fourth
International Conference on the Chemistry and Uses of Molybdenum, H.F. Barry and P.C.H. Mitchell, eds.,
Climax Molybdenum Company, Ann Arbor, Michigan, 1982, pp. 79-82. L.F. Rhodes, M.A. Green, J.C.
Huffman, and K.G. Caulton.
5. "Photochemistry of Transition Metal Hydrides: Dimerization of OsH 4 (PMe 2 Ph) 3 Following Photodissociation
of Dihydrogen," J. Organomet. Chem., 243, C78-82 (1983). M.A. Green, J.C. Huffman, and K.G. Caulton.
6. "The Photochemistry of Rhenium Hydrides. A Flash Photolytic Investigation of the Transients in the
Photochemistry of ReH 5 (PMe 2 Ph) 3 ," J. Organomet. Chem., 244, 47-59 (1983). S. Muralidharan, G. Ferraudi,
M.A. Green, and K.G. Caulton.
7. "Synthesis and Crystallographic Characterization of a Gallium Salicylaldimine Complex of
Radiopharmaceutical Interest," J. Am. Chem. Soc., 106, 3689-3691 (1984). M.A. Green, M.J. Welch, and J.C.
Huffman.
8. "1,1,1-Tris(5-methoxysalicylaldiminomethyl)ethane: A Chelating Agent for the Preparation of Lipophilic
Gallium and Indium Radiopharmaceuticals," J. Labelled Compounds and Radiopharmaceuticals, 21, 1001-
1002 (1984). M.A. Green, C.J. Mathias, and M.J. Welch.
9. "Chemical and Biological Studies of Ga-68 1,1,1-Tris(5-methoxysalicylaldiminomethyl)ethane: A Potential
Tracer for Evaluation of Regional Myocardial Blood Flow by Positron Emission Tomography," J. Nucl. Med.,
26, 170-180 (1985). M.A. Green, M.J. Welch, C.J. Mathias, K.A.A. Fox, R.M. Knabb, and J.C. Huffman.
10. "Photoinitiated Intramolecular Hydrogen Transfer from Rhenium Polyhydrides to C 8 Cyclopolyolefins,"
Organometallics, 4, 514-519 (1985). M.C.L. Trimarchi, M.A. Green, J.C. Huffman, and K.G. Caulton.
11. "Regional Lung Water and Hematocrit Determined by Positron Emission Tomography," J. Appl. Physiol., 59,
860-868 (1985). D.P. Schuster, M.A. Mintun, M.A. Green, and M.M. Ter-Pogossian. M.A. Mintun, M.A.
Green, and M.M. Ter-Pogossian.
12. "Hydride-Rich Zirconium-Osmium and Zirconium-Rhenium Dimers," J. Am. Chem. Soc., 105, 8310-3212
(1984). J.W. Bruno, J.C. Huffman, M.A. Green, and K.G. Caulton.
13. "Radiopharmaceuticals Labeled with Short-Lived Positron-Emitting Radionuclides," Radioisotopes (Japan)
34, 170-179 (1985). M.J. Welch, M.R. Kilbourn, and M.A. Green.
14. "A Lipophilic Salt of a Transition Metal Polyhydride: KOsH 3 (PMe 2 Ph) 3 ," J. Am. Chem. Soc., 107, 5111-5115
(1985). J.C. Huffman, M.A. Green, S.L. Kaiser, and K.G. Caulton.
3

PUBLICATIONS (continued):
15. "Evaluation of PLED as a Chelating Ligand for the Preparation of Gallium and Indium Radiopharmaceuticals,"
Int. J. Nucl. Med. Biol., 12, 381-386 (1985). M.A. Green, M.J. Welch, C.J. Mathias, P. Taylor, and A.E.
Martell.
16. "Quantitative Measurement of Regional Pulmonary Blood Flow with Positron Emission Tomography," J. Appl.
Physiol., 60, 317-326 (1986). M.A. Mintun, M.M. Ter-Pogossian, M.A. Green, L.L. Lich, and D.P. Schuster.
17. "New Chelates for the Preparation of Indium and Gallium Radiopharmaceuticals," J. Labelled Compounds and
Radiopharmaceuticals, 23, 1221-1222 (1986). C.J. Mathias, M.J. Welch, M.A. Green, J.A. Thomas, A.E.
Martell, and Y. Sun.
18. "Synthesis and Biodistribution of a Series of Lipophilic Gallium-67 Tris(salicylaldimine) Complexes," J.
Labelled Compounds and Radiopharmaceuticals, 23, 1227-1229 (1986). M.A. Green.
19. "A Potential Copper Radiopharmaceutical for Imaging the Heart and Brain," Nucl. Med. Biol, 14, 59-61
(1987). M.A. Green.
20. "Positron Emission Tomography of the Lung," in Pulmonary Nuclear Medicine, M.K. Loken, ed., Appleton-
Century-Crofts, New York, 1987. D.P. Schuster and M.A. Green.
21. "The Molecular Structure of Indium Oxine," J. Nuclear Medicine, 29, 417-420, 1988. M.A. Green and J.C.
Huffman.
22. "Targeting Radiopharmaceuticals: Comparative Biodistribution Studies of Gallium and Indium Complexes of
Multidentate Ligands," Nucl. Med. Biol., 15, 69-81, 1988. C.J. Mathias, Y. Sun, M.J. Welch, M.A. Green, J.A.
Thomas, K. Waade, and A.E. Martell.
23. "Copper(II) Bis(thiosemicarbazone) Complexes as Potential Tracers for Evaluation of Cerebral and
Myocardial Blood Flow with PET," J. Nuclear Medicine, 29, 1549-1557 (1988). M.A. Green, D.L.
Klippenstein, and J.R. Tennison.
24. "Gallium Radiopharmaceutical Chemistry (Review)," Nucl. Med. Biol., 16, 435-448, 1989. M.A. Green and
M.J. Welch.
25. "Radiopharmaceuticals for Positron Emission Tomography (PET)," in Principles and Practice of Nuclear
Medicine, 2nd Edition, P.J. Early and D.B. Sodee, editors, Mosby, St. Louis, 1994, pages 739-751. M.A.
Green and M.J. Welch.
26. "Gallium-68 Labeled Macroaggregated Human Serum Albumin, 68 Ga-MAA," Nucl. Med. Biol., 16, 319-321,
1989. G.A. Even and M.A. Green.
27. "Structure-Activity Relationships for Metal-Labeled Blood Flow Agents: Comparison of Copper(II)
Bis(thiosemicarbazone) Derivatives," J. Labeled Compounds & Radiopharmaceuticals, 26 351-353, 1989.
M.A. Green and E. John.
28. "Correlation of Cu(PTSM) Localization with Regional Blood Flow in the Heart and Kidney," Nucl. Med. Biol.,
16, 747-748, 1989. A.J. Barnhart, W.D. Voorhees, and M.A. Green.
29. "Structural Characterization of a Metal-Based Perfusion Tracer: Copper(II) Pyruvaldehyde Bis(N 4 -Methylthiosemicarbazone),"
Nucl. Med. Biol., 16, 791-797, 1989. E. John, P.E. Fanwick, A.T. McKenzie, J.G.
Stowell, and M.A. Green.
4

PUBLICATIONS (continued):
30. "Kinetics of Copper-PTSM in Isolated Hearts: A Novel Tracer for Measuring Blood Flow with Positron
Emission Tomography," J. Nucl. Med., 30, 1843-1847, 1989. M.E. Shelton, M.A. Green, C.J. Mathias, M.J.
Welch, and S.R. Bergmann.
31. "Assessment of Regional Myocardial and Renal Blood Flow using Copper-PTSM and Positron Emission
Tomography," Circulation, 82, 990-997, 1990. M.E. Shelton, M.A. Green, C.J. Mathias, M.J. Welch, and S.R.
Bergmann.
32. "Evaluation of a Potential Generator-Produced PET Tracer for Cerebral Perfusion Imaging: Single-Pass
Cerebral Extraction Measurements and Imaging with Radiolabeled Cu(PTSM)." J. Nucl. Med., 31, 351-359,
1990. C.J. Mathias, M.J. Welch, M.E. Raichle, M.A. Mintun, L.L. Lich, A.H. McGuire, K.R. Zinn, E. John,
and M.A. Green.
32. "Structure and Reactivity of ReH 4 (PMe 2 Ph) 4 + ," Inorg. Chem., 28, 4527-4531, 1989. D.M. Lunder, M.A.
Green, W.E. Streib, and K.G. Caulton.
33. "Structure-Activity Relationships for Metal-Labeled Blood Flow Tracers: Comparison of Ketoaldehyde
Bis(thiosemicarbazonato)copper(II) Derivatives," J. Med Chem. , 33, 1764-1770, 1990. E.K. John and M.A.
Green.
34. "Photodissociation of H 2 and PMe 2 Ph Occur Simultaneously from OsH 4 (PMe 2 Ph) 3 ", Organometallics, 9,
2556-2567, 1990. J.W. Bruno, J.C. Huffman, M.A. Green, J.D. Zubkowski, W.E. Hatfield, and K.G. Caulton.
35. "Acute Toxicity and Mutagenicity of the Copper Complex of Pyruvaldehyde Bis(N 4 -
methylthiosemicarbazone), Cu-PTSM." J. Applied Toxicology, 10, 417-421, 1990. P.J. Kostyniak, A.E.
Maccubbin, S.M. Nakeeb, E.K. John, M.A. Green, E.M. Schopp, and H.F. Kung.
36. "[ 62 Cu]-Labeled Pyruvaldehyde Bis(N 4 -methylthiosemicarbazonato)copper(II): Synthesis and Evaluation as a
Positron Emission Tomography Tracer for Cerebral and Myocardial Perfusion," J. Nucl. Med., 31, 1989-1996,
1990. M.A. Green, C.J. Mathias, M.J. Welch, F. Fernandez-Rubio, J.S. Perlmutter, M.E. Raichle, and S.R.
Bergmann.
37. "A Remote System for the Synthesis of Copper-62 Labeled Cu(PTSM)," Applied Radiation and Isotopes, 42,
317-320, 1991. C.J. Mathias, W.H. Margenau, J.W. Brodack, M.J. Welch, and M.A. Green.
38. "In Vivo Comparison of Copper Blood Pool Agents: Potential Radiopharmaceuticals for Use with Copper-
62," J. Nucl. Med., 32, 475-480, 1991. C.J. Mathias, M.J. Welch, M.A. Green, H. Diril, C.F. Meares, R.J.
Gropler, and S.R. Bergmann.
39. "The Potential for Generator-Based PET Perfusion Tracers," J. Nucl. Med., 31, 1641-1645, 1990. M.A. Green.
40. "Gallium and Copper Radiopharmaceutical Chemistry" in New Trends in Radiopharmaceutical Synthesis,
Quality Assurance and Regulatory Control, A.M. Emram, editor, Plenum, New York, 1991, pp. 119-127.
M.A. Green.
41. "Investigation of Cu-PTSM as a PET Tracer for Tumor Blood Flow," Nucl. Med. Biol., 18, 807-811, 1991.
C.J. Mathias, M.J. Welch, D.J. Perry, A.H. McGuire, X. Zhu, J.M. Connett, and M.A. Green.
5

PUBLICATIONS (continued):
42. "Reactions of ReH 7 (PPh 3 ) 2 with 1-Diphenylphosphino-2-diphenylarsinoethane (arphos) and Bis(1,2-
diphenylarsinoethane (dpae). The Structural Characterization of ReH 5 (PPh 3 ) 2 (arphos-As) and
ReH 5 (PPh 3 ) 2 (dpae-As). Inorg. Chem., 30, 861-864, 1991. M.T. Costello, P.E. Fanwick, M.A. Green, and
R.A. Walton.
43. "The Effects of Glutathione Depletion on the Biodistribution of Cu(PTSM) in Rats" Nucl. Med. Biol., 18, 865-
869, 1991. A. Barnhart Bott and M.A. Green.
44. "Evaluation of the gastric retention properties of a crosslinked polymer coated tablet versus those of a
nondisintegrating tablet. Int. J. Pharm., 75, 241-247, 1991. G.A. Agyilirah, M.A. Green, R. DuCret, and G.S.
Banker.
45. "PET Imaging with Metal Radionuclides" in Advances in Metals in Medicine, Volume 1, M.J. Abrams and
B.A. Murrer, editors, JAI Press, Greenwich, CT, 1993, pages 75 - 114. M.A. Green.
46. "Myocardial Perfusion Imaging with Copper-62 Labeled Cu-PTSM" in What's New in Cardiac Imaging?,
E.E. Van der Wall, H. Sochor, A. Righetti, and M.G. Niemeyer, editors, Kluwer Academic Publishers,
Dordrecht, The Netherlands, 1992. Pages 165-177. M.A. Green.
47. "Subcellular Distribution of Tissue Radiocopper Following Intravenous Administration of 67 Cu-Labeled Cu-
PTSM." Nucl. Med. Biol., 19, 697-701, 1992. I.D. Baerga, R.P. Maickel, and M.A. Green.
48. "Potential Gallium-68 Tracers for Imaging the Heart with Positron Emission Tomography: Evaluation of Four
Gallium Complexes with Functionalized Tripodal Tris(salicylaldimine) Ligands." J. Nuclear Medicine, 34,
228-233, 1993. M.A. Green, C.J. Mathias, W.L. Neumann, M.Janik, and E.A. Deutsch.
49. "Quantification of Regional Myocardial Perfusion with Generator-Produced Copper-62-PTSM and Positron
Emission Tomography." Circulation, 87, 173-183, 1993. P. Herrero, J. Markham, C.J. Weinheimer, C.J.
Anderson, M.J. Welch, M.A. Green, and S.R. Bergmann.
50. "Rhenium Polyhydride Complexes that Contain the Tripodal Phosphine CH 3 C(CH 2 PPh 2 ) 3 (triphos)."
Inorganic Chemistry, 31, 2359-2365, 1992. M.T. Costello, P.E. Fanwick, M.A. Green,, and R.A. Walton.
51. "Development and Validation of a Solvent Extraction Technique for Determination of Cu-PTSM in Blood."
Nucl. Med. Biol., 20, 343-349, 1993. C. J. Mathias, S.R. Bergmann, and M.A. Green.
52. "A Gallium-68 Radiopharmaceutical that is Retained in Myocardium: 68 Ga[4,6-MeO 2 sal) 2 BAPEN] + ." J.
Nucl. Med., 34, 1127-1131, 1993. B.W. Tsang, C.J. Mathias, and M.A. Green.
53. "Preparation and Biodistribution of Copper-67 Complexes with Tetradentate Schiff-Base Ligands." J. Pharm.
Sci., 83, 587 - 590, 1994. E.K. John, A.J. Bott, and M.A. Green.
54. "Synthesis and Structure of a Five Coordinate Triarylgallium Complex. J. Chem. Soc., Chem. Comm., 14,
1127-1129, 1993. D.K. Coggin, P.E. Fanwick, and M.A. Green.
6

PUBLICATIONS (continued):
55. " 62 Cu-PTSM: A Generator-Based PET Radiopharmaceutical for Myocardial Perfusion Imaging." In: Cardiac
Positron Emission Tomography, M.Schwaiger, editor, Kluwer Academic Publishers, Boston, 1996, pages 161-
172. M.A. Green.
56. "Investigation of [ 67 Ga]-dimethylgallium(III) acetylacetonate as a potential radiopharmaceutical." Nucl. Med.
Biol., 21, 283-285, 1994. D. K. Coggin, C. J. Mathias, and M. A. Green.
57. "Evaluation of Cu-PTSM as a Tracer of Tumor Perfusion: Comparison with Labeled Microspheres in
Spontaneous Canine Neoplasms." Nucl. Med. Biol., 21, 83 - 87, 1994. C. J. Mathias, M. A. Green, W. B.
Morrison, and D. W. Knapp.
58. "Structure-Distribution Relationships for Metal-Labeled Myocardial Imaging Agents: Comparison of a Series
of Cationic Gallium(III) Complexes with Hexadentate Bis(salicylaldimine) Ligands," J. Med. Chem., 37:4400-
4406; 1994. B.W. Tsang, C.J. Mathias, P.E. Fanwick, and M.A. Green.
59. "Synthesis and Crystal Structure of a Copper(II) Complex with a Tetradentate Dithiadioxime Ligand."
Polyhedron, 14:1097-1100; 1995. S.P. Wey, A.M. Ibrahim, M.A. Green, and P.E. Fanwick.
60. "Species-Dependent Binding of Copper(II) Bis(thiosemicarbazone) Radiopharmaceuticals to Serum Albumin."
J. Nucl. Med., 36:1451-1456; 1995. C.J. Mathias, S.R. Bergmann, and M.A. Green.
61. "Release of Cu-PTSM from Human Serum Albumin After Addition of Fatty Acids." J. Inorg. Biochem.,
61:251-259; 1996. H Yuan, W.E. Antholine, W.K. Subczynski, and M.A. Green.
62. "Synthesis and Biodistribution of Indium(III) Complexes with Hexadentate Bis(salicylaldimine) Ligands."
Journal of Labelled Compounds and Radiopharmaceuticals, 37:770-772; 1995. S.P. Wey, Y.M. Hsiao, C.J.
Mathias, and M.A. Green.
63. "Synthesis, Purification, and Tumor Cell Uptake of 67 Ga-Deferoxamine-Folate Conjugate, a Potential
Radiopharmaceutical for Tumor Imaging." Bioconjujate Chemistry, 7:56-62; 1996. S. Wang, R.J. Lee, C.J.
Mathias, M.A. Green, and P.S. Low.
64. "Tumor-Selective Radiopharmaceutical Targeting via Receptor-Mediated Endocytosis: Evaluation of a
Gallium-67 Labeled Folate-Deferoxamine Conjugate." Journal of Nuclear Medicine, 37:1003-1008; 1996.
C.J. Mathias, S. Wang, R.J. Lee, D.J. Waters, P.S. Low, and M.A. Green.
65. "Assessment of Regional Myocardial Perfusion with Generator-Produced 62 Cu-PTSM and PET in Human
Subjects." Journal of Nuclear Medicine 37:1294-1300; 1996. P. Herrero, J.J. Hartman, M.A. Green, C.J.
Anderson, M.J. Welch, J. Markham, and S.R. Bergmann.
66. "Indium-111 Labeled Indium(III)-DTPA-Folate as a Radiopharmaceutical for Targeting Tumor-Associated
Folate Receptors: The Effect of Tumor Size on Targeting Selectivity and Radiochemical Analysis of Excreted
Tracer." J. Labelled Compounds and Radiopharmaceuticals, 40:365-367; 1997. C.J. Mathias, D.J. Waters, S.
Wang, P.S. Low, and M.A. Green.
7

PUBLICATIONS (continued):
67. "Biodistribution of Lipophilic Monocationic 67 Ga-Bis(salicylaldimine) Radiotracers, 99m Tc-Sestamibi, and
18 F-FDG in an MDA-MB-435 Mammary Tumor Mouse Model." J. Labelled Compounds and
Radiopharmaceuticals, 40:368-370; 1997. C.J. Mathias, S.-P. Wey, G.W. Sledge, Jr., and M.A. Green.
68. "Radiolabeling of SPARC-Derived Angiogenic Copper peptides with Copper-67 and Copper-64." J. Labelled
Compounds and Radiopharmaceuticals, 40:499-500; 1997. C.J. Mathias and M.A. Green.
69. "Mixed Bis(thiosemicarbazone) Ligands for Preparation of Copper Radiopharmaceuticals: Synthesis and
Evaluation of Tetradentate Ligands Containing Two Dissimilar Thiosemicarbazone Functions," J. Med.
Chem., 40:132-136; 1997. J.K. Lim, C.J. Mathias, and M.A. Green.
70. "Synthesis and Evaluation of a Monocationic Copper(II) Radiopharmaceutical Derived from N-(2-
Pryidylmethyl)-N'-(salicylaldimino)-1,3-propanediamine," Nucl. Med. Biol., 25:107-110; 1998. M. Sri-Aran,
C.J. Mathias, J.K. Lim, and M.A. Green.
71. "Synthesis and Structure of a Novel Copper(II) Complex with a Monoprotic Tetradentate Schiff-Base Ligand,"
Inorg. Chem., 37:1127-1130; 1998. H.Luo, P.E. Fanwick, and M.A. Green.
72. "Research Radionuclide Availability in North America - Part 1," J. Nucl. Med., 38:15N-19N; 1997. L.E.
Ketchum, M.A. Green, and S.S. Jurisson.
73. "Research Radionuclide Availability in North America - Part 2," J. Nucl. Med., 38:21N-22N, 28N, 47N-48N;
1997. L.E. Ketchum, M.A. Green, and S.S. Jurisson.
74. "Design and Synthesis of 111 In-DTPA-Folate for Use as a Tumor-Targeted Radiopharmaceutical," Bioconj.
Chem., 8:673-679; 1997. S. Wang, J. Luo, D.A. Lantrip, D.J. Waters, C.J. Mathias, M.A. Green, P.L. Fuchs,
and P.S. Low.
75. "Copper-62 Radiopharmaceuticals for Diagnostic Imaging with Positron Emission Tomography (PET),"
Transition Metal Chemistry, 22:427-429; 1997. M.A. Green.
76. "Evaluation of 111 In-DTPA-Folate as a Potential Folate-Receptor-Targeted Radiopharmaceutical," J. Nucl.
Med., 39:1579-1585, 1998. C.J. Mathias, S. Wang, D.J. Waters, J.J. Turek, P.S. Low, and M.A. Green.
77. "Human Biodistribution and Dosimetry of the PET Perfusion Agent 62 Cu-PTSM from a Compact Modular
62 Zn/ 62 Cu Generator," J. Nucl. Med., 39:1958-1964; 1998. T.R. Wallhaus, J. Lacy, J. Whang, M.A. Green,
R.J. Nickles, and C.K. Stone.
78. "Receptor-Mediated Targeting of 67 Ga-Deferoxamine-Folate to Folate-Receptor-Positive Human KB Tumor
Xenografts," Nucl. Med. Biol., 26:23-25; 1999. C.J. Mathias, S. Wang, P.S. Low, D.J. Waters, and M.A.
Green.
79. "A Kit Formulation for Preparation of [ 111 In]In-DTPA-Folate, a Folate-Receptor-Targeted
Radiopharmaceutical," Nucl. Med. Biol., 25:585-587; 1998. C.J. Mathias and M.A. Green.
80. "Tetradentate Schiff-Base ligands for Possible Use in Preparation of Estrogen-Mimetic Copper
Radiopharmaceuticals," J. Labelled Cpd. Radiopharm. 42:S246-248; 1999. Z. Wang, Y. Guan, P.E. Fanwick,
D.E. Bergstrom, and M.A. Green.
8

PUBLICATIONS (continued):
81. "Gallium(III) Schiff-Base Complexes as Potential PET Agents for Evaluation of Multidrug Resistance
(MDR1) P-Glycoprotein Transport Activity," J. Labelled Cpd. Radiopharm. 42:S723-725; 1999. V. Sharma,
V. Polyakov, A. Beatty, S.-P. Wey, L. Bass, J. Dahlheimer, C.L. Crankshaw, M.A., Green, M.J. Welch, and D.
Piwnica-Worms.
82. "Synthesis and Evaluation of Folate-Bis(thiosemicarbazone) and Folate-CYCLAM Conjugates for Possible
Use as Folate-Receptor-Targeted Copper Radiopharmaceuticals. J. Labelled Cpd. Radiopharm. 42:S821-823;
1999. C.-Y. Ke, C.J. Mathias, Z.-F. Yang, J. Luo, P.S. Low, D.J. Waters, and M.A. Green.
83. "Stereocontrolled Synthesis of (R,R,S)- and (S,R,S)-3,4-Diaminocyclopentanols." SYNLETT 1999:426-428. Y.
Guan, D.E. Bergstrom, and M.A. Green.
84. "Synthesis and Evaluation of Copper Radiopharmaceuticals with Mixed Bis(thiosemicarbazone) Ligands,"
Nucl. Med. Biol. 26:551-554; 1999. L.J. Ackerman, D.X. West, C.J. Mathias, and M.A. Green.
85. "Monoprotic Tetradentate N 3 O-Donor Ligands and Their Cu(II) and Ni(II) Complexes," Inorganic Chemistry,
38:2071-2078; 1999. H. Luo, J-M Lo, P.E. Fanwick, J.G. Stowell, and M.A. Green.
86. "Performance of a Zn-62/Cu-62 Generator in Clinical Trials of the PET Perfusion Agent 62 Cu-PTSM," J.
Nucl. Med. 41:309-314; 2000. N.G. Haynes, J.L. Lacy, N. Nayak, C.S. Martin, D. Dai, C.J. Mathias, and M.A.
Green.
87. "Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for
probing P-glycoprotein-mediated transport activity in vivo," Chemistry and Biology, 7:335-343; 2000. V.
Sharma, A. Beatty, S.P. Wey, L. Bass, C.L. Crankshaw, M.A. Green, M.J. Welch, and D. Piwnica-Worms.
88. "Copper(II) and Nickel(II) Complexes of Pyruvaldehyde Mixed Bis(N(4)-substituted thiosemicarbazones},"
Polyhedron 18:2759-2767; 1999. L.J. Ackerman, P.E. Fanwick, M.A. Green, E. John, W.E. Running, J.K.
Swearingen, J.W. Webb, and D.X. West.
89. “Copper-62-pyruvaldehyde bis(N-4-methylthiosemicarbazone) PET imaging in the Detection of Coronary
Artery Disease in Humans,” J. Nucl. Cardiol. 8:67-74; 2001. T.R. Wallhaus, J. Lacy, R. Stewart, J. Bianco,
M.A. Green, and C.K. Stone.
90. "Synthesis of [ 99m Tc]-Tc-DTPA-Folate and Its Evaluation as a Folate-Receptor-Targeted
Radiopharmaceutical," Bioconjugate Chemistry 11:253-257; 2000. C.J. Mathias, D. Hubers, P.S. Low, and
M.A. Green.
91. “Synthesis of Compound Libraries Based on 3,4-Diaminocyclopentanol Scaffolds,” Journal of Combinatorial
Chemistry 2:297-300; 2000. Y. Guan, M.A. Green, and D.E. Bergstrom.
92. “Cis-3,4-diaminocyclopentanol Complexes of Platinum(II),” Inorganica Chimica Acta 307:57-62; 2000. Z.
Wang, Y. Guan, P.E. Fanwick, J.G. Stowell, D.E. Bergstrom, and M.A. Green.
93. "Chemistry of Copper Radionuclides and Radiopharmaceutical Products," in Handbook of
Radiopharmaceuticals: Radiochemistry and Applications, M.J. Welch and C.S. Redvanly, editors, Wiley:West
Sussex, England, 2003; pages 401-422. C.J. Anderson, M.A. Green, and Y. Fujibayashi.
94. "Synthesis and Evaluation of 99m Tc(CO) 3 -DTPA-Folate as a Folate-Receptor-Targeted Radiopharmaceutical,"
Nuclear Medicine and Biology, 29:569-573; 2002. D.P. Trump, C.J. Mathias, Z. Yang, P.S. Low, M.
Marmion, and M.A. Green.
9

95. “Evaluation of 111 In-DTPA-Folate as a Receptor-Targeted Diagnostic Agent for Ovarian Cancer: Initial
Clinical Results,” Journal of Nuclear Medicine, 44;700-707; 2003. B.A. Siegel, F. Dehdashti, D.A. Mutch,
D.A. Podoloff, R. Wendt, G.P. Sutton, R.W. Burt, R. Ellis, C.J. Mathias, M.A. Green, D.M. Gershenson.
96. "Preparation of Ga-66- and Ga-68-labeled Ga(III)-deferoxamine-folate as Potential Folate-receptor-targeted
PET Radiopharmaceuticals," Nuclear Medicine & Biology, 30:725-731; 2003. C.J. Mathias, M.R. Lewis, D.E.
Reichert, R. Laforest, T.L. Sharp, J.S. Lewis, Z.F. Yang, D.J. Waters, P.W. Snyder , P.S. Low, M.J. Welch,
M.A. Green.
97. "The Folate Receptor as a Molecular target for Tumor-Selective Radionuclide Delivery," Nuclear Medicine &
Biology, 30:811-817; 2003.
98. "Folate-receptor-targeted Radionuclide Imaging Agents," Advanced Drug Delivery Reviews, 56:1143-1160;
2004. C.Y. Ke, C.J. Mathias, and M.A. Green.
99. "Targeting the Tumor-Associated Folate Receptor with a 111 In-DTPA Conjugate of Pteroic Acid." J. Am.
Chem. Soc.,127: 7421-7426; 2005. C.Y. Ke, C.J. Mathias, and M.A. Green.
100. "Assessment of Cu-ETS as a PET Radiopharmaceutical for Evaluation of Regional Renal Perfusion." Nucl.
Med. Biol. 34:247-255; 2007. M.A. Green, C.J. Mathias, L.R. Willis, R.K. Handa, J.L. Lacy, M.A. Miller, and
G.D. Hutchins.
101. "Species dependence of [ 64 Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins,"
Nucl Med Biol 35:281-286, 2008. Nathan E. Basken, Carla J. Mathias, Alexander E. Lipka, Mark A. Green.
102. "A convenient route to [ 68 Ga]Ga-MAA for use as a particulate PET perfusion tracer, Applied Radiation and
Isotopes, 66:1910-1912; 2008. C.J. Mathias and M.A. Green.
103. "Synthesis and Biodistribution of Lipophilic Monocationic Gallium Radiopharmaceuticals Derived from N,N'-
bis(3-aminopropyl)-N,N'-dimethylethylenediamine: Potential Agents for PET Myocardial Imaging with 68 Ga."
Nucl. Med. Biol., 36:39-45; 2009. Yui-May Hsiao, Carla J. Mathias, Shiaw-Pyng Wey, Phillip E. Fanwick, and
Mark A. Green.
104. "Elucidation of the Human Serum Albumin (HSA) Binding Site for the Cu-PTSM and Cu-ATSM
Radiopharmaceuticals," J Pharm Sci., 98:2170-2179; 2009. N.E. Basken, C.J. Mathias, and M.A. Green.
105. "Cu(II) Bis(thiosemicarbazone) Radiopharmaceutical Binding to Serum Albumin: Further Definition of
Species-Dependence and Associated Substituent Effects," Nucl Med Biol, 36:495-504; 2009. N.E. Basken, and
M.A. Green.
PATENTS
"Radiopharmaceuticals for Imaging the Heart," M.A. Green and B.W. Tsang, U.S. Patent No. 5,324,502; June
28, 1994. (For gallium and indium radiopharmaceuticals that are retained in myocardium.)
"Method for Enhanced Transmembrane Transport of Exogenous Molecules," P.S. Low, M.A. Horn, M.A.
Green, C.J. Mathias, R.J. Lee, C.P. Leamon, and P.F. Heinstein. Provisional Application Filed May 16, 1995.
(For radiopharmaceuticals targeted to tumor-associated folate receptors.)
"Drug Targeting with Non-peptide Folate Mimetics," M.A. Green and C.Y. Ke. U.S. Provisional Patent
Application Filed, April 2001. Subsequent patent application; Folate mimetics and Folate-receptor Binding
10

Conjugates Thereof, M.A. Green, C.P. Leamon, and C-Y Ke, Filed April 24, 2002.
European Patent No. 1389209, Issued April 8, 2009.
Preparation of folate mimetics and folate-receptor binding conjugates thereof
By Green, Mark A.; Leamon, Christopher P.; Ke, Chun-Yen
From PCT Int. Appl. (2002), WO 2002085908 A1 20021031.
11

RESEARCH GRANT SUPPORT
Current Support:
Whole-Body PET/CT Assessment of Tumor Perfusion Using Generator-Produced 62 Cu
R01 CA140299-01 (Fletcher, Green, Lacy) 8/1/09-7/31/13
This project is evaluating a non-invasive PET method for assessment of tumor perfusion using generator-produced
copper-62. The proposed method will be suitable for implementation at any clinical PET center in the U.S.,
complementing current clinical whole-body PET 18 F-FDG studies to assess tumor metabolism. The project's clinical
focus is patients with head-and-neck cancer. Patients will receive the investigational 62 Cu-ETS radiopharmaceutical
for "whole-body" PET/CT imaging to assess tumor perfusion immediately prior to scheduled standard baseline and
post-therapy clinical PET/CT with 18 F-FDG. Patients will also be imaged using 15 O-water to provide an independent
reference measure of tumor perfusion for validation of 62 Cu-ETS. Global and regional measures of tumor perfusion
will be compared to the findings from 18 F-FDG imaging, as well as to changes in tumor size using RECIST criteria
and to the patient's clinical response to treatment.
Other Research Activities:
Collaborating investigator - NCI Research Resource for Production of Short-Lived Biomedical
Radionuclides, Washington University, St. Louis, MO
Collaborating Investigator - Indiana Center of Excellence in Biomedical Imaging, State of Indiana, 21 st
Century Research and Technology Fund.
12

Previous Funding:
"Copper Radiopharmaceuticals for Imaging the Heart and Brain," Mark A. Green, Principal Investigator,
Minnesota Medical Foundation, Direct Costs: $5,000/1 year, 11/85-11/86.
"Lipophilic Copper Radiopharmaceuticals for Imaging the Brain and Heart," Mark A. Green, Principal
Investigator, The Society of Nuclear Medicine, Education and Research Foundation, Direct Costs: $3,000,
3/87-2/88.
"Radiopharmaceuticals from Generator-Produced Nuclides," Mark A. Green, Principal Investigator,
National Institutes of Health, Research Career Development Award, 1 K04 HL 01801. Total Costs:
$281,387; 8/86-7/91.
"Radiopharmaceuticals Labeled with Metal Radionuclides," Mark A. Green, Principal Investigator,
National Institutes of Health, 1 R01 CA 46909, Total Costs: $292,661; 6/87-5/90.
"Synthesis of Bifunctional Chelating Agents for Use in Cancer Diagnosis and Therapy," Purdue Cancer
Center, 4/88-6/89, Total Costs: $10,000 Co-PI, Mark A. Green and Elizabeth K. John.
"Technetium Radiopharmaceuticals for Evaluation of Myocardial Blood Flow," Mark A. Green, Principal
Investigator, American Heart Association-Indiana Affiliate, Total Costs: $24,297, 7/89-6/91.
"Molecular Modeling in the Development of Metal Radiopharmaceuticals," Mark A. Green, Principal
Investigator, U.S. Department of Energy, Total Costs: $263,274, 7/89-6/92.
"Radiopharmaceuticals Labeled with Metal Radionuclides," (Competing Renewal, R01-CA46909), M.A.
Green, Principal Investigator, National Institutes of Health, Annual Direct Costs: $147,186 (year 1); Total
Costs (6/90-5/95): $895,348.
"Synthesis and Evaluation of Gallium Tris(salicylaldimine) Radiopharmaceuticals," M.A. Green, Principal
Investigator, Mallinckrodt Medical, Inc., Total Costs: $10,000, 7/91-12/91.
"Synthesis and Evaluation of Gallium Radiopharmaceuticals," M. A. Green, Principal Investigator,
Mallinckrodt Medical, Inc., Total Costs: $49,998, 7/92-12/93.
"Gallium Radiopharmaceuticals for the Diagnosis of Coronary Artery Disease with Positron Emission
Tomography," American Heart Association - Indiana Affiliate (Post-doctoral Fellowship supporting Dr.
Brenda Tsang), Total Costs: $37,000, 7/92 - 6/94.
"Purdue as a Site for a Dedicated U.S. Isotope Production Facility," K.L. Kliewer and M.A. Green,
Principal Investigators, Indiana Business Modernization and Technology Corporation, Total Costs:
$52.000. 4/93 - 12/94.
"National Biomedical Tracer Facility – Project Definition Study," M.A. Green, Principal Investigator, U.S.
Department of Energy, Office of Health and Environmental Research, DE-FG02-94ER61872. Total Costs:
$303,267. 8/1/94 - 6/15/95
"Development of a Copper-62 PET Perfusion Agent," Mark A. Green, Principal Investigator, NIH STTR
Program, R41-HL53067-01, 8/1/94- 2/29/96. Phase I STTR Project to develop commercially-viable
synthetic methods for Cu-62 radiopharmaceuticals in collaboration with Proportional Technologies, Inc.,
Houston, Texas. Total Cost- $100,000.
13

Previous Funding (continued):
"Development of a Copper-62 PET Perfusion Agent," Mark A. Green, P.I. NIH/NHLBI R42-HL53067-
02, 9/30/96-2/28/99. Total Annual Costs: $255,454 ($125,000 Purdue Subcontract). Phase II STTR
Project to develop commercially-viable synthetic methods for Cu-62 radiopharmaceuticals in collaboration
with Proportional Technologies, Inc., Houston, Texas. This Phase II STTR effort involves preclinical and
Phase 1 clinical investigation of copper-62 labeled radiopharmaceuticals for evaluation of myocardial
perfusion.
Development of 178 Ta Myocardial Blood Flow Tracers," Mark A. Green, Principal Investigator for
Purdue subcontract. NIH/NHLBI R43-HL57075-01 (Raghuvir Singh, P.I.), 9/30/96-3/29/97. Total Costs:
$91,300 ($25,010 Purdue Subcontract) This 6-month subcontract to Purdue University was part of a Phase
1 SBIR project of Proportional Technologies, Inc., Houston, TX.
"Receptor-Targeted Metalloradiopharmaceuticals," Mark A. Green, Principal Investigator, U.S. Dept. of
Energy - Office of Energy Research (OHER), 12/1/96-2/29/00.
14
Annual Costs (Direct/Total)
$194,345/$279,937. The major goals of this project are the design, synthesis, and evaluation of metallabeled
radiopharmaceuticals designed to target breast-tumor-associated estrogen receptors.
"Radiopharmaceuticals Targeted to Tumor Folate Receptors, " Mark A. Green, Principal Investigator,
NIH/NCI R01-CA70845, 6/15/96 - 5/31/99. Annual Costs (Direct/Total) $179,916/$272,739. Project
involves investigation of radiopharmaceutical targeting to tumors via tumor-cell-membrane-associated
folate receptors.
Collaborative effort with Professors Philip Low (Chemistry) and David Waters
(Veterinary Clinical Sciences).
(Renewed 3/1/00)
"A Novel Targeted Radiopharmaceutical for Tumor Imaging," Mark A. Green, P.I., Purdue Subcontract,
NIH/NCI via Endocyte, Inc., R42-CA73260, 9/29/97-9/28/99. Total costs (Purdue subcontract) $24,793.
Phase 1 SBIR project of Endocyte, Inc., West Lafayette, IN. The goal of the project was to commercially
develop In-111-DTPA-folate as a radiopharmaceutical for imaging folate-receptor-positive tumors, most
notably ovarian carcinoma. Focused on assisting with initiation of Phase 1 & 2 Clinical Trials by
development of a kit formulation for radiopharmaceutical compounding.
"A Novel Targeted Radiopharmaceutical for Tumor Imaging," Mark A. Green, P.I., Purdue Subcontract,
NIH/NCI Phase 2 SBIR Project via Endocyte, Inc., R43-CA73260, 9/29/97-9/28/99. Annual costs (Purdue
subcontract) $23,829.
The goal of the project is to commercially develop In-111-DTPA-folate as a
radiopharmaceutical for imaging folate-receptor-positive tumors, most notably ovarian carcinoma.
Subcontract focuses on assisting with initiation of Phase 1 & 2 Clinical Trials and development of
methodology for analysis of radiotracer metabolism.
"A Novel Targeted Tc-99m Radiopharmaceutical for Tumor Imaging - Radiolabeling Conditions and Initial
Animal Studies," Mark A. Green, P.I., Purdue Subcontract, NIH/NCI Phase 1 SBIR Project via Endocyte,
Inc. West Lafayette, IN, R44-CA80435. 11/1/98-4/30/99. Total cost (Purdue subcontract): $20,008. The
goal of the project is to develop, and evaluate, a Tc-99m-labeled folate conjugate for use as a
radiopharmaceutical for imaging folate-receptor-positive tumors, most notably ovarian carcinoma.
“Radiopharmaceuticals Targeted to Tumor Folate Receptors," Mark A. Green, Principal Investigator
(30% effort), NIH/NCI R01-CA70845, 3/1/00 - 2/29/04. Present Annual Costs (Direct/Total)
$218/$481,837. Project is investigating radiopharmaceutical targeting to tumors via tumor-cell-membraneassociated
folate receptors. Collaborative effort with Professors Philip Low (Chemistry) and David Waters
(Veterinary Clinical Sciences).
“Purdue University Nuclear Pharmacy Educational Program," Mark A. Green, Principal Investigator
(10% effort), U.S. Department of Energy - Advanced Nuclear Medicine Initiative. 4/1/01 - 3/31/04. First

Year Costs (Direct/Total) $109,082/$119,280. Project will establish PET radiochemistry laboratory
modules in the Purdue University nuclear pharmacy curriculum, and provide partial salary support for an
individual at the Indiana University School of Medicine charged with supervising nuclear pharmacy
students during their elective Pharm.D. advanced clerkship rotation, NUPH 595: Clerkship in Nuclear
Medicine.
“Chelate-Based Scaffolds ("CHELABODY") in Tumor Imaging,” Principal Investigator Joseph R. Garlich,
Ph.D., ComChem Technologies, Inc. Subcontract P.I. Mark A. Green (10% effort), NCI FLAIR Grant
R41-CA92835, 9/1/2001 - 8/31/2003. This project focuses on the synthesis and evaluation of radiolabeled
metal chelates as tumor-vasculature-targeted radiopharmaceuticals. Combinatorial chemistry techniques
are being applied as tools for identification and optimization of radiometal chelates targeted to receptors
associated with tumor angiogenesis.
“Regional Renal Perfusion Quantification with Cu-62 PET,” Principal Investigator: Jeffrey Lacy, Ph.D.,
Proportional Technologies, Inc. Subcontract P.I. Mark A. Green (5% effort). NIH/NIDDKD: R43
DK58466, 7/1/01 - 3/31/02 The major goal of this SBIR project is validation of Cu-62-ETS as a PET
radiopharmaceutical for quantification of regional renal perfusion.
The project is being pursued in
collaboration with the renal physiology group at the I.U. School of Medicine, and Proportional
Technologies Inc. of Houston, TX. Very positive validation results have been obtained indicating that we
can use the agent 62 Cu-ETS to non-invasively measure regional renal perfusion (mL blood per minute per
gram of tissue) with PET; the renal physiology group is now ready to apply this method in studying renal
damage following shock-wave lithotripsy.
“Regional Renal Perfusion Quantification with Cu-62 PET,” Principal Investigator: Jeffrey Lacy, Ph.D.,
Proportional Technologies, Inc. Subcontract P.I. Mark A. Green (15% effort). NIH/NIDDKD: R44
DK58466, 9/1/03 - 2/28/06 The major goal of this SBIR project is validation of Cu-62-ETS as a PET
radiopharmaceutical for quantification of regional renal perfusion.
The project is being pursued in
collaboration with the renal physiology group at the I.U. School of Medicine, and Proportional
Technologies Inc. of Houston, TX. Very positive validation results have been obtained indicating that we
can use the agent 62 Cu-ETS to non-invasively measure regional renal perfusion (mL blood per minute per
gram of tissue) with PET; the renal physiology group is now ready to apply this method in studying renal
damage following shock-wave lithotripsy.
"PET Radiotracers to Evaluate Tumor Multidrug Resistance" Principal Investigator: Mark A. Green,
Ph.D. (20% effort) Agency: NIH/(NCI) Type: R01-CA92403, 4/1/03-3/31/08. Project focuses on design,
synthesis, and evaluation of novel chiral radiogallium chelates for non-invasive PET assessment of the
MDR1 Pgp transport function associated with multi-drug resistance.
15

EDUCATIONAL ACTIVITIES
Teaching Responsibilities:
NUPH 530: Applied Nuclear Pharmacy (3 cr). Co-instructed with Kara Duncan, Pharm.D. Directly
responsible for ~60% of course lectures and for instruction in the course laboratory that meets in
two sections weekly. Primary lecture topics include radiopharmaceutical chemistry and principles
of drug design for physiological imaging. (Since Fall, 1987)
NUPH 550: Introduction to Positron Emission Tomography (PET) (2 cr). New course created to provide
the students with an introduction to the theory and practice of diagnostic imaging with positron
emission tomography (PET).
NUPH 595: Clerkship in Nuclear Medicine (4 credits, may be repeated once for credit). This course is a
4-week clerkship rotation in the Division of Nuclear Medicine at the Indiana University School of
Medicine . It is intended for Pharm.D. students who wish to enter the practice of clinical nuclear
pharmacy and who have completed the nuclear pharmacy elective course sequence on the Purdue
West Lafayette campus. This rotation is designed to develop the nuclear pharmacist's clinical
knowledge and skills with regard to diagnostic and therapeutic nuclear medicine and associated
pharmacy practice through direct interactions with patients, physicians, technologists, and other
nuclear medicine staff. The contributions of nuclear medicine to patient care are evaluated through
the study of individual clinical cases and outcomes.
NUPH 490: Research in Nuclear Pharmacy/Radiopharmaceutical Chemistry. Laboratory research
experiences for undergraduate nuclear pharmacy students.
Graduate students advised (degree):
Post-doctoral associates trained:
Amy J. Barnhart (Ph.D.)
Ingrid Baerga (M.S.)
Sim Sim Lim (M.S.)
Diana Tribbey (M.S.)
Tony Roberts (M.S.)
Shiaw-Pyng Wey (Ph.D.)
Moleephan Sri-Aran (M.S.)
David Trump (Ph.D.)
Eric Smith (current M.S./Pharm.D.)
Richard Walulu (M.S.)
Elizabeth John, Ph.D.
Adrian Bott, Ph.D.
Peter Wade, Ph.D.
DeAnna Coggin, Ph.D.
Brenda W. Tsang, Ph.D.
John K. Lim, Ph.D.
Yui-May Hsiao, Ph.D.
Roger Luo, Ph.D.
Zheng Wang, Ph.D.
A.C. Dumaual, Ph.D.
Chun-Yen Ke, Ph.D.
Devansen Loganathan, Ph.D.
16

EDUCATIONAL ACTIVITIES (continued):
Pharmacy Continuing Education:
Lecturer for Nuclear Pharmacy Certificate Program on the topics of PET imaging, principles of
inorganic chemistry in nuclear pharmacy, and drug design principles in physiological imaging.
(Approximately 6 lecture hours in each certificate program session. These sessions have been offered 3
times per year since April 1989.)
Other University Service:
Faculty Advisor, Purdue Juggling Club, 1988-90.
Faculty Advisor, Rho Chi (Pharmacy Honor Society), 7/96-present
Purdue Radiological Control Committee, 7/97-present.
Purdue Committee on Use of Human Subjects in Research (IRB), 7/98-present.
OTHER PROFESSIONAL ACTIVITIES
Invited participant in National Academy of Sciences, National Research Council Workshop on Training
Requirements for Chemists in Nuclear Medicine, Nuclear Industry, and Related Areas; National Academy of
Sciences, Washington, D.C., 2/88.
Organizer of continuing education session, "Radiopharmaceuticals from Generator-Produced Nuclides," for
Society of Nuclear Medicine 35th Annual Meeting, San Francisco, CA, 6/88.
Invited Participant in Department of Energy Workshop on "The Role of a High-Current Accelerator in the Future
of Nuclear Medicine," R.J. Oppenheimer Study Center, Los Alamos National Laboratory, Los Alamos, NM, 8/88.
Member, Scientific Program Committee, Society of Nuclear Medicine 36th Annual Meeting, June, 1989.
Category Subchairman for Technetium Radiopharmaceuticals; responsible for reviewer selection, abstract review,
and program assembly.
Chairman/Chairman-elect, Purdue Section, American Chemical Society, 1990-91.
Served as reviewer for scientific research proposals submitted to the U.S. Department of Energy, Office of Health
and Environmental Research, in the area of radiopharmaceutical chemistry (1996)
Co-Organizer of the Purdue National Biomedical Tracer Facility Workshop, West Lafayette, IN, April 28 - 30,
1992 (with Assistant Vice President for Research Kenneth L. Kliewer).
Member, Board of Directors, Society of Nuclear Medicine Radiopharmaceutical Science Council, 6/91-5/93.
Member, Society of Nuclear Medicine Special Committee on Research (appointed by Society President), 6/93-
6/95.
Service on NIH-NHLBI Special Study Section for Program Project Review (1995).
Member, Advisory Committee, Physiologic Imaging Research Center (PIRC), Indiana University School of
Medicine, (formerly PET Research/Users Committee), 1/93 - 1997.
Coordinator for Translational Research, Purdue Cancer Center, 7/94 - 6/98.
Service on NIH-NHLBI Special Study Section for Program Project Review (1996).
External Thesis Examiner, University of British Columbia, Department of Chemistry (1996).
Member, External Advisory Committee, Brookhaven National Laboratory – National Isotope Center, 4/96-8/97.
Service on NIH-NHLBI Special Study Section for Program Project Review (1998)
17

Service on Scientific Review Panel on Innovative Treatments, California Breast Cancer Research Program (4/99)
Service on NIAID Special Study Section for Immunological Phenotyping of Mouse Mutants (8/99)
Service as scientific reviewer for applications to the Department of Energy SBIR Program (1999)
Program Committee - 46th Annual Meeting of the Society of Nuclear Medicine (2000)
Service as scientific reviewer for applications to the Department of Energy SBIR Program (6/00).
Service on Scientific Review Panel, Department of Energy - Advanced Nuclear Medicine Initiative, Washington,
D.C. (8/00)
Service as Scientific Merit Reviewer for the Roy J. Carver Charitable Trust, Muscatine, Iowa (9/00).
Program Committee - 47th Annual Meeting of the Society of Nuclear Medicine (2001)
Appointed member, Chemistry Department Advisory Board, Rose-Hulman Institute of Technology, Terre Haute,
IN (10/00).
Service on Scientific Review Panel on Innovative Treatments, California Breast Cancer Research Program (3/01)
Service as Scientific Merit Reviewer for Veterens Administration (3/02).
Service as Scientific Merit Reviewer for the California Breast Cancer Research Fund, San-Francisco (4/02).
Invited Panel Member – DOE Workshop on Radiochemistry Research Resources, Chicago (4/02).
Member, Executive Committee, Indiana Center of Excellence in Biomedical Imaging (funded through the State of
Indiana 21 st Century Research and Technology Fund and based at the Indiana University School of Medicine).
18